Study Summary
This trial is comparing Instylla HES to standard of care transarterial embolization/conventional transarterial chemoembolization to see if it is effective and safe.
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
2 Primary · 0 Secondary · Reporting Duration: Immediately post-embolization procedure
Trial Safety
Phase-Based Safety
Awards & Highlights
Trial Design
2 Treatment Groups
Control
1 of 2
Instylla HES
1 of 2
Active Control
Experimental Treatment
150 Total Participants · 2 Treatment Groups
Primary Treatment: Instylla HES · No Placebo Group · N/A
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 0 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
How many participants have been accepted into this research program?
"To carry out this scientific endeavour, 150 patients who meet the inclusion requirements need to be identified. Instylla, Inc., is managing the trial from a number of centres such as Boston Medical Center in Massachusetts and Northwell Health, Inc. located in Manhasset, New York." - Anonymous Online Contributor
Are there any centers in the US that are currently undertaking this research?
"Boston Medical Center in Boston, Massachusetts, Northwell Health Inc. in Manhasset, New York and University of Colorado Anschutz Medical Center in Aurora, Colorado are just 3 out the 17 clinical trial sites delivering this treatment." - Anonymous Online Contributor
Are there any slots still available for this experiment?
"According to information found on clinicaltrials.gov, this research project is presently looking for test subjects. The trial was initially uploaded on April 1st 2021 and the last update occurred November 4th 2022." - Anonymous Online Contributor